Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.

ABSTRACT:

Background

Treatment multiple tumors by immune therapy can be achieved by mobilizing both innate and adaptive immunity. The programmed death ligand 1 (PD-L1; or CD274, B7-H1) is a critical "don't find me" signal to the adaptive immune system. Equally CD47 is a critical "don't eat me" signal to the innate immune system and a regulator of the adaptive immune response.

Method

Both of CD47 and PD-L1 are overexpressed on the surface of cancer cells to enable to escape immune-surveillance. We designed EpCAM (epithelial cell adhesion molecule)-targeted cationic liposome (LPP-P4-Ep) containing si-CD47 and si-PD-L1 could target high-EpCAM cancer cells and knockdown both CD47 and PD-L1 proteins.

Findings

Efficient silencing of CD47 and PD-L1 versus single gene silencing in vivo

SUBMITTER: Lian S 

PROVIDER: S-EPMC6491392 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature